TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22975068
Drug: Ghrelin administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ghrelin administration for controlling postoperative cytokine storm
Study: 19414681
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all‐trans retinoic acid (ATRA) and chemotherapy, maintenance treatment, escalating doses of cytarabine, early administration of dexamethasone, and CNS prophylaxis.
Study: 19414681
Drug: Enrollment onto
Normalized name: Ontosein
DrugBank: Orgotein (DB11444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrollment onto the APL 2000 trial and combined maintenance with ATRA and chemotherapy.
Study: 19414681
Drug: APL 93
Normalized name: APL-502
DrugBank: APL-502 (DB17473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APL 93 trial (previous standard treatment).
Study: 14535877
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg daily for 8 weeks
Study: 7594328
Drug: Clarithromycin 200
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 200 mg twice daily for 2 weeks and Lansoprazole 30 mg daily for 8 weeks
Study: 2890307
Drug: Continuous medication
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous medication
Study: 1974743
Drug: Targeted medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted medication
Study: 31069957
Drug: Vaginal insert
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal insert (tablet)
Study: 27247202
Drug: Vaginal gel
Normalized name: VAGINAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal gel
Study: 31069957
Drug: On-demand products
Normalized name: Gel-One Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand products (film, insert, gel)
Study: 19967619
Drug: Pico-Salax (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pico-Salax (sodium picosulphate with magnesium citrate), administered in two doses: one the evening before and one on the morning of the procedure
Study: 19967619
Drug: PEG‐ELS (polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐ELS (polyethylene glycol with electrolyte solution), administered over 4 hours
Study: 15077265
Drug: Prednisone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (10 mg/day)
Study: 8001300
Drug: K-strophanthin (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-strophanthin (0.125 mg intravenously)
Study: 8001300
Drug: Digoxin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.25 mg orally)
Study: 2968749
Drug: Prednisolone sodium
Normalized name: Prednisolone Sodium Phosphate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone sodium tetrahydrophthalate followed by oral prednisone for 2 days
Study: 2968749
Drug: Aldosterone followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone followed by oral 9 alpha fludrocortisone for 2 days
Study: 27146798
Drug: Standard supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard supportive treatment (Control Group)
Study: 24266309
Drug: Endoscopic hemoclips
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic hemoclips therapy (group I)
Study: 24266309
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of hemoclips and epinephrine (group II)
Study: 16449027
Drug: rhIGF-I at
Normalized name: rhIGF-I/rhIGFBP-3
DrugBank: Mecasermin rinfabate (DB14751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhIGF-I at 80 microg/kg body weight daily (n = 6)
Study: 16449027
Drug: rhIGF-I at
Normalized name: rhIGF-I/rhIGFBP-3
DrugBank: Mecasermin rinfabate (DB14751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhIGF-I at 40 microg/kg twice daily (n = 6)
Study: 16449027
Drug: rhIGF-I at
Normalized name: rhIGF-I/rhIGFBP-3
DrugBank: Mecasermin rinfabate (DB14751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhIGF-I at 80 microg/kg twice daily (n = 6)
Study: 12566183
Drug: Ambulatory epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory epidural analgesia (intermittent epidural injections of 0.1% ropivacaine with 0.6 microg/ml sufentanil)
Study: 12566183
Drug: Non-ambulatory epidural
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ambulatory epidural analgesia (intermittent epidural injections of 0.1% ropivacaine with 0.6 microg/ml sufentanil)
Study: 10693153
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of d,l‐fenfluramine (intervention group: bulimia nervosa remitted)
Study: 10693153
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of d,l‐fenfluramine (intervention group: current bulimia nervosa)
Study: 10984081
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg sublingual)
Study: 30535217
Drug: 0.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 μg of oral alfacalcidol per day (intervention group; n=495)
Study: 30535217
Drug: Treatment without
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment without vitamin D receptor activators (control group; n=481)
Study: 12553505
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg meloxicam
Study: 23648081
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil 50 mg (group FT)
Study: 16906017
Drug: Alfentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil at concentrations of 0, 33.33, 66.67, and 100 ng/ml
Study: 14516427
Drug: Combined surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined surgery group (360 degrees scleral buckling, pars plana vitrectomy, air-fluid exchange, endolaser, injection of 14% perfluoropropane gas)
Study: 10905242
Drug: Regular inhaled
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular inhaled salbutamol 400 microg four times daily for 12 months
Study: 10905242
Drug: Regular inhaled
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular inhaled salbutamol 400 microg four times daily
Study: 9216092
Drug: TT5 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TT5 (5 days treatment with furazolidone 600 mg/day, metronidazole 750 mg/day, amoxicillin 1.5 g/day)
Study: 9216092
Drug: TT10 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: TT10 (10 days treatment with furazolidone 600 mg/day, metronidazole 750 mg/day, amoxicillin 1.5 g/day)
Study: 6712199
Drug: Mezlocillin, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezlocillin, 4 g every 6 h
Study: 6712199
Drug: Carbenicillin, 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenicillin, 7.5 g every 6 h
Study: 6712199
Drug: Placebo, 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 0.9% NaCl, 50 ml every 6 h
Study: 23982113
Drug: Omega-3 (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 (1.8 g daily for 12 weeks)
Study: 19683191
Drug: Betaxolol 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 0.25% (twice daily)
Study: 19683191
Drug: TGFS 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGFS 0.25% (daily)
Study: 19683191
Drug: TGFS 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGFS 0.5% (daily)
Study: 8913399
Drug: Ceftriaxone 500
Normalized name: ceftriaxone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 500 mg in 2 mL of lidocaine 1% solution (250 mg/mL)
Study: 8913399
Drug: Ceftriaxone 500
Normalized name: ceftriaxone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 500 mg in 1.4 mL of lidocaine 1% solution (350 mg/mL)
Study: 1862788
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day desipramine
Study: 1862788
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day amantadine-placebo
Study: 30933317
Drug: Yoga during
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga during treatment
Study: 30933317
Drug: Yoga post-treatment
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Yoga post-treatment
Study: 27545747
Drug: Integrated Approach
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Approach of Yoga Therapy (IAYT)
Study: 17566756
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 830 and 633nm LED phototherapy
Study: 17566756
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment light
Study: 26442394
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone 0.5 mg.kg(‐1)
Study: 31116017
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment control condition
Study: 16201937
Drug: Meropenem (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (500 mg IV q8h)
Study: 16201937
Drug: Imipenem-cilastatin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem-cilastatin (500 mg IV q8h)
Study: 12899226
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg doxazosin daily for 3 months
Study: 10599899
Drug: Usual activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual activities of daily living (Control group)
Study: 8566836
Drug: Acetyl salicylic
Normalized name: Acetyl salicylic acid specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl salicylic acid (ASA) 650 mg three times daily
Study: 8566836
Drug: Effervescent calcium
Normalized name: Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent calcium carbasalate (ECC) 826.8 mg three times daily
Study: 2011771
Drug: d-penicillamine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-penicillamine (500 mg/day)
Study: 27306620
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg apixaban twice daily (n=9120)
Study: 27306620
Drug: Warfarin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (target INR range 2.0-3.0; n=9081)
Study: 18807583
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg tablet formulation A
Study: 18807583
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg tablet formulation B
Study: 16297323
Drug: Reduced Glutathione
Normalized name: Reduced glutathione
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced Glutathione (GSH) 1.2 g/d through intravenous drip for 7 days
Study: 10100041
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + metronidazole tabs 200 mg tds for 7 days
Study: 10100041
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + 2 subgingival applications of 25% metronidazole gel
Study: 85106
Drug: Bay g
Normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bay g 6575 (1.2 g daily for 1 week)
Study: 85106
Drug: Bay g
Normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bay g 6575 (1.2 g single dose)
Study: 85106
Drug: Bay g
Normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bay g 6575 and dipyridamole (combined administration)
Study: 85106
Drug: Bay g
Normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bay g 6575 (alone)
Study: 27583214
Drug: Aminobisphosphonate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminobisphosphonate solution
Study: 20059657
Drug: Dynamic infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dynamic infusion cavernosometry and cavernosography (DICC)
Study: 11753000
Drug: 0.07 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.07 mg/kg neostigmine administered upon reappearance of the first tactile TOF response (group I)
Study: 11753000
Drug: 0.07 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.07 mg/kg neostigmine administered upon reappearance of the second tactile TOF response (group II)
Study: 11753000
Drug: 0.07 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.07 mg/kg neostigmine administered upon reappearance of the third tactile TOF response (group III)
Study: 11753000
Drug: 0.07 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.07 mg/kg neostigmine administered upon reappearance of the fourth tactile TOF response (group IV)
Study: 11753000
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not explicitly defined, but implied as no neostigmine administration)
Study: 2283012
Drug: PGE2‐gel (Prepidil)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2‐gel (Prepidil) intravaginal
Study: 17277392
Drug: Anti-vascular endothelial
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-vascular endothelial growth factor agents
Study: 26957836
Drug: New pharmacologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New pharmacologic agents
Study: 24328907
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate 0.1% cream (BMVc)
Study: 24328907
Drug: Tacrolimus 0.1%
Normalized name: TACROLIMUS 0.1% OINT,TOP
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus 0.1% ointment (TACo)
Study: 22521875
Drug: 100mg hydrocortisone
Normalized name: hydrocortisone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg hydrocortisone given as a rapid intravenous bolus
Study: 16328453
Drug: intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: intradermal injection of 50 microg capsaicin without cooling
Study: 16328453
Drug: injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of capsaicin followed by application of 0 degrees C cold pain stimulation
Study: 1473164
Drug: Allylestrenol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allylestrenol (30 mg/d initially, reduced to 5 mg/d after 15 days)
Study: 1473164
Drug: Lynestrenol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lynestrenol (10 mg/d initially, reduced to 1.25 mg/d)
Study: 6143138
Drug: Maintenance of
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance of activity, anti-inflammatory and antirheumatic drugs, and systemic steroids where necessary
Study: 6143138
Drug: Rest and
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rest and anti-inflammatory and antirheumatic drugs
Study: 30559259
Drug: Sutimlimab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sutimlimab (10 mg/kg test dose followed by 60 mg/kg full dose 1 to 4 days later and 3 additional weekly doses of 60 mg/kg)
Study: 27797093
Drug: Selective Spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Spinal Lidocaine (SS-L): 3 mL of 0.8% lidocaine solution (24 mg lidocaine, 15 μg fentanyl)
Study: 27797093
Drug: Conventional Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Dose Lidocaine (CD-L): 5 mL of 1% lidocaine solution (50 mg lidocaine, 25 μg fentanyl)
Study: 25361563
Drug: PCPPP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCPPP treatment group
Study: 18060250
Drug: Antithrombotic pharmacobiologic
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic pharmacobiologic therapy
Study: 16128945
Drug: Bi-weekly endoscopic
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bi-weekly endoscopic variceal ligation (EVL)
Study: 16128945
Drug: Bi-monthly endoscopic
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi-monthly endoscopic variceal ligation (EVL)
Study: 12401580
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg bolus followed by a 4 mg/min infusion during operation and 4 mg/kg in the priming solution of CPB)
Study: 7798579
Drug: Low-fat controlled
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat controlled diet plus 20 g corn bran supplement
Study: 7798579
Drug: Low-fat controlled
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat controlled diet plus 20 g wheat bran supplement
Study: 2086820
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (CXM-AX) 250 mg t.i.d. for 3-7 days
Study: 2086820
Drug: Cefaclor (CCL)
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor (CCL) 250 mg t.i.d. for 3-7 days
Study: 765515
Drug: 600,000 units
Normalized name: Wycillin, 600,000 units/mL intramuscular suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600,000 units of penicillin G benzathine
Study: 765515
Drug: 1.2 million
Normalized name: penicillin G benzathine 1.2 million unit INTRAMUSC VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 million units of penicillin G benzathine
Study: 765515
Drug: 600,000 units
Normalized name: Wycillin, 600,000 units/mL intramuscular suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600,000 units of penicillin G benzathine and 600,000 units of penicillin G procaine
Study: 765515
Drug: 900,000 units
Normalized name: Bicillin C-R 900/300, 900,000 units-300,000 units/2 mL intramuscular suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900,000 units of penicillin G benzathine and 300,000 units of penicillin G procaine
Study: 24118640
Drug: Linagliptin 2.5
Normalized name: linagliptin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 2.5 mg plus metformin 1000 mg bid
Study: 24118640
Drug: Linagliptin 2.5
Normalized name: linagliptin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 2.5 mg plus metformin 500 mg bid
Study: 24118640
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg bid
Study: 24118640
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg bid
Study: 31297968
Drug: Linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 5 mg qd
Study: 15102334
Drug: Response to
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response to treatment as a predictor of LOS
Study: 15102334
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) as a predictor of LOS
Study: 2998786
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Metoprolol (beta 1‐selective)
Study: 2998786
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg Propranolol (non‐selective)
Study: 28820949
Drug: Synthetic cartilage
Normalized name: SHARK CARTILAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic cartilage implant MTPJ1 hemiarthroplasty
Study: 24499493
Drug: NRL001 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRL001 5 mg, 7.5 mg, or 10 mg in 1 or 2 g suppositories
Study: 24499493
Drug: NRL001 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRL001 10 mg, 12.5 mg, or 15 mg in 1 or 2 g suppositories
Study: 24499493
Drug: NRL001 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRL001 doses (1 g and 2 g)
Study: 24499493
Drug: NRL001 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRL001 doses
Study: 19345644
Drug: EVT 201
Normalized name: EVT 201
DrugBank: EVT 201 (DB05721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVT 201 1.5 mg
Study: 19345644
Drug: EVT 201
Normalized name: EVT 201
DrugBank: EVT 201 (DB05721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVT 201 2.5 mg
Study: 17351300
Drug: Sprinkles 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprinkles 12.5 mg ferrous fumarate
Study: 17351300
Drug: Sprinkles 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprinkles 20 mg ferrous fumarate
Study: 17351300
Drug: Sprinkles 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprinkles 30 mg ferrous fumarate
Study: 17351300
Drug: Sprinkles 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprinkles 20 mg micronized ferric pyrophosphate
Study: 17351300
Drug: DROPS 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: DROPS 20 mg ferrous glycine sulphate
Study: 15364158
Drug: Preprandial dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preprandial dosing of BIAsp 30 (b.i.d. injections before meals)
Study: 15364158
Drug: Postprandial dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial dosing of BIAsp 30 (b.i.d. injections after meals)
Study: 15364158
Drug: Postprandial dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial dosing of BIAsp 30
Study: 15364158
Drug: Preprandial dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preprandial dosing of BIAsp 30
Study: 15364158
Drug: Postprandial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial injection
Study: 11454372
Drug: Low-dose combined
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combined spinal epidural (n=351)
Study: 11454372
Drug: Low-dose infusion
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose infusion epidural (n=350)